ClinicalTrials.gg
Not yet recruitingNCT07947875Updated Nov 19, 2026

Impact of Spinal Mobilizations on Pain Modulation in People With Low Back Pain.

An interventional study of Grade II central posterior-to-anterior spinal mobilization and Grade IV central posterior-to-anterior spinal mobilization in Low Back Pain, sponsored by New York Institute of Technology. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by New York Institute of Technology · Not applicable, Interventional, and Treatment

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Research shows 85% of the population will experience at least one episode of low back pain (LBP) in their lifetime. The annual cost to manage LBP in the U.S. can exceed 2 billion dollars. A conservative approach to LBP management can be provided by a physical therapist through interventions such as spinal mobilization. Spinal mobilizations are graded (I-IV) based upon the varying depths and impulse frequency at which they are applied to the target tissue. Functional magnetic resonance imaging (fMRI) studies have shown that spinal mobilizations (grade III, grade V) can stimulate pain suppression and provide favorable neurophysiological effects on pain modulation.

No studies to date, however, have examined the neurophysiological influence of grades II and IV on pain modulation. The purpose of this study is to investigate the change in pain suppression following spinal mobilization (i.e., grades II and IV).

Read the detailed description

A conservative approach to LBP management can be provided by a physical therapist through interventions such as spinal mobilization. Spinal mobilizations are defined as passive movements to the spinal joints at varying speeds and amplitudes to restore accessory motion and optimize joint function. Spinal mobilizations are graded (I-IV) based upon the varying depths and impulse frequency in which they are applied to the target tissue. Grades I and II are applied more superficially to the tissue just prior to the onset of tissue resistance. These grades are often used for pain modulation in individuals who report high levels of pain and may present as reactive and irritable. Grades III and IV are applied deeper into the tissue resistance and are primarily used to increase tissue extensibility and joint mobility. These grades are often used with individuals who primarily report stiffness and mobility loss with lower levels of pain.

A proposed mechanism associated with spinal mobilization is the neurophysiological influence on pain modulation through activation of descending inhibitory pathways. Functional magnetic resonance imaging (fMRI) studies have shown that spinal mobilizations (grade III, grade V) can stimulate the salience network and provide favorable neurophysiological effects on pain modulation. This is determined by measuring the change in peak blood-oxygen-level-dependent (BOLD) signal from predefined regions of interest (ROIs). These ROIs include the prefrontal cortex, precuneus, anterior/posterior insulas, thalamus, anterior/posterior cingulate cortices, somatosensory cortex, secondary somatosensory cortex, and periaqueductal gray. Computing correlations between region pairs will determine functional connectivity (FC) and show which brain regions are most active.

No studies to date have examined the neurophysiological influence of grades II or IV on the salience network stimulation and pain modulation. These grades vary greatly with respect to their frequency and depth of application but may still provide similar pain modulation outcomes. The purpose of this study is to investigate the change in salience network stimulation following spinal mobilization (i.e., grades II and IV).

02

Conditions studied

  • Low Back Pain

Keywords

  • back pain
  • pain relief
  • spinal mobilizations
03

In context

Low Back Pain

2,930 studies on the registry are indexed under Low Back Pain; 580 are open to participants now.

This study's planned enrollment of 10 is below the median of 60 across 2,368 interventional studies indexed under Low Back Pain.

Browse Low Back Pain studies →

Lead sponsor

New York Institute of Technology is the lead sponsor of 60 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A. New York Tech students B. Age range: at least 18 years old C. Good overall health D. Mechanical low back pain ≥ 1 month *(source of pain is muscular or skeletal) E. Pain intensity of at least 4/10 or greater

Exclusion criteria

Exclusion Criteria:

A. Claustrophobia B. IEDs including: pacemakers, internal defibrillators, and insulin pumps C. Medical implants or metallic foreign bodies, not limited ferrous metals D. Any previous history of lumbar surgery, nerve root involvement, stenosis (narrowing of the spinal canal), or mechanical instability E. Pregnancy F. Use of opioid medication G. LBP secondary to disease or systemic cause H. History of cardiovascular disease or high blood pressure I. History of Type I or Type II Diabetes J. History of neurodevelopmental disorders K. Prolonged * use *(e.g., prednisone, dexamethasone, hydrocortisone, etc.) L. Oswestry Low Back Disability Index (ODI) score of \<5 M. Inability to provide

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Grade II lumbar spine mobilization

    A grade II posterior-to-anterior spinal mobilization will be applied to the individual's lumbar spine for a total of five minutes.

    Other: Grade II central posterior-to-anterior spinal mobilization

  • Experimental
    Grade IV lumbar spinal mobiliation

    A grade IV posterior-to-anterior spinal mobilization will be applied to the individual's lumbar spine for a total of five minutes.

    Other: Grade IV central posterior-to-anterior spinal mobilization

Interventions

  • OtherGrade II central posterior-to-anterior spinal mobilization

    A grade II spinal mobilization is applied to the spinal segment in a posterior-to-anterior direction to a tissue depth before the first onset of tissue resistance.

  • OtherGrade IV central posterior-to-anterior spinal mobilization

    Grade IV central posterior-to-anterior spinal mobilization will be applied to the lumbar spine for five minutes to a tissue depth of 50% of the tissue resistance.

06

What researchers measure

Primary outcomes

  1. Numeric Pain Rating Scale

    This 11-point numeric scale ranges from '0' representing one pain extreme (e.g., "no pain") to '10' representing the other pain extreme (e.g., "pain as bad as you can imagine" or "worst pain imaginable").

    Time frame: At both sessions of care, from enrollment to the end of treatment at week 2

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Gay CW, Robinson ME, George SZ, Perlstein WM, Bishop MD. Immediate changes after manual therapy in resting-state functional connectivity as measured by functional magnetic resonance imaging in participants with induced low back pain. J Manipulative Physiol Ther. 2014 Nov-Dec;37(9):614-27. doi: 10.1016/j.jmpt.2014.09.001. Epub 2014 Oct 3. PubMed 25284739 ↗
  • Zhou XC, Wu S, Wang KZ, Chen LH, Hong SW, Tian Y, Hu HJ, Lin J, Wei ZC, Xie YX, Yin ZH, Lv ZZ, Lv LJ. Default mode network and dorsal attentional network connectivity changes as neural markers of spinal manipulative therapy in lumbar disc herniation. Sci Rep. 2024 Nov 28;14(1):29541. doi: 10.1038/s41598-024-81126-2. PubMed 39604454 ↗
  • Isenburg K, Mawla I, Loggia ML, Ellingsen DM, Protsenko E, Kowalski MH, Swensen D, O'Dwyer-Swensen D, Edwards RR, Napadow V, Kettner N. Increased Salience Network Connectivity Following Manual Therapy is Associated with Reduced Pain in Chronic Low Back Pain Patients. J Pain. 2021 May;22(5):545-555. doi: 10.1016/j.jpain.2020.11.007. Epub 2020 Dec 13. PubMed 33321196 ↗
  • Chimenti RL, Frey-Law LA, Sluka KA. A Mechanism-Based Approach to Physical Therapist Management of Pain. Phys Ther. 2018 May 1;98(5):302-314. doi: 10.1093/ptj/pzy030. PubMed 29669091 ↗
  • Bialosky JE, Beneciuk JM, Bishop MD, Coronado RA, Penza CW, Simon CB, George SZ. Unraveling the Mechanisms of Manual Therapy: Modeling an Approach. J Orthop Sports Phys Ther. 2018 Jan;48(1):8-18. doi: 10.2519/jospt.2018.7476. Epub 2017 Oct 15. PubMed 29034802 ↗
  • Hanrahan S, Van Lunen BL, Tamburello M, Walker ML. The Short-Term Effects of Joint Mobilizations on Acute Mechanical Low Back Dysfunction in Collegiate Athletes. J Athl Train. 2005 Jun;40(2):88-93. PubMed 15970954 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Feb 2027, 3 months later.

Of 1,234 non-industry interventional studies with no phase under Low Back Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's planned 3 months is below that.

Counting every sponsor, half of 1,290 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2026
First posted
Nov 19, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Feb 1, 2027
CompletionEst.
May 1, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07947875
Lead sponsor
New York Institute of Technology
Responsible party
Mark Gugliotti (Associate Professor, New York Institute of Technology) — Principal investigator
First posted
Nov 19, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Feb 1, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Mark Gugliotti, DPT
Contact
mgugliot@nyit.edu
6315125559
Mark Gugliotti, DPT
principal investigator · NYIT

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion